Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.
Type | Public | |
Founded | 1968 | |
HQ | Mumbai, IN | Map |
Website | lupin.com | |
Employee Ratings |
INR | |
---|---|
Revenue (Q3, 2022) | 40.9b |
Gross profit (Q3, 2022) | 25.0b |
Net income (Q3, 2022) | 5.5b |
EBITDA (Q3, 2022) | 4.0b |
EBIT (Q3, 2022) | 2.0b |
Market capitalization (26-May-2022) | 293.8b |
Closing stock price (26-May-2022) | 600.5 |
EV | 293.8b |
INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 155.5b | 163.7b | 166.0b | 149.3b |
Cost of goods sold | (57.5b) | (63.1b) | (59.7b) | (59.2b) |
Gross profit | 100.5b | 104.1b | 108.6b | 92.9b |
R&D expense | (18.4b) | (15.8b) | (15.1b) | (14.3b) |
INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 37.7b | 38.9b | 43.8b | 43.6b | 43.0b | 37.2b | 34.7b | 37.8b | 39.2b | 42.4b | 40.0b | 40.9b |
Cost of goods sold | (14.4b) | (13.9b) | (16.0b) | (15.5b) | (15.3b) | (13.6b) | (12.9b) | (13.8b) | (13.7b) | (15.3b) | (16.3b) | (16.9b) |
Gross profit | 26.0b | 27.9b | 29.5b | 29.4b | 29.6b | 25.0b | 22.8b | 24.8b | 26.6b | 27.7b | 25.3b | 25.0b |
R&D expense | (3.8b) | (3.8b) | (425.7m) | (3.8b) | 3.8b |
INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 14.1b | 9.9b | 24.5b | 17.4b |
Accounts Receivable | 51.9b | 51.5b | 54.5b | 44.7b |
Prepaid Expenses | 5.1b | 5.2b | 6.8b | 2.9b |
Inventories | 36.6b | 38.4b | 34.6b | 40.9b |
INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 10.9b | 11.6b | 13.2b | 12.8b | ||||||||
Accounts Receivable | 52.0b | 49.2b | 48.0b | 43.1b | ||||||||
Prepaid Expenses | 2.0b | 123.9m | ||||||||||
Inventories | 38.5b | 41.1b | 40.2b | 44.7b |
INR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | 5.5b | 15.2b | 7.6b | 16.8b |
Depreciation and Amortization | 10.9b | 10.9b | 11.6b | 8.9b |
Inventories | 172.7m | (2.9b) | (4.8b) | (6.6b) |
Accounts Payable | (305.8m) | (1.6b) | 5.6b | (3.7b) |
INR | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 | Q1, 2022 | Q2, 2022 | Q3, 2022 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.4b | 6.3b | (14.5b) | |||||||||
Depreciation and Amortization | 6.4b | 4.3b | 11.3b | |||||||||
Inventories | (2.6b) | (5.9b) | (3.9b) | |||||||||
Accounts Payable | 1.6b | (206.0m) | 3.4b |
INR | FY, 2018 |
---|---|
Revenue/Employee | 9.3m |
Lupin revenue breakdown by business segment: 100.0% from PHARMACEUTICAL
Lupin has 38 Twitter Followers. The number of followers has increased 3.8% quarter over quarter
When was Lupin founded?
Lupin was founded in 1968.
Who are Lupin key executives?
Lupin's key executives are Manju D Gupta, Kamal K Sharma and Richard Zahn.
How many employees does Lupin have?
Lupin has 18,573 employees.
What is Lupin revenue?
Latest Lupin annual revenue is ₹149.3 b.
What is Lupin revenue per employee?
Latest Lupin revenue per employee is ₹8 m.
Who are Lupin competitors?
Competitors of Lupin include Mito BioPharma, Sciwind and Tetra Therapeutics.
Where is Lupin headquarters?
Lupin headquarters is located at Laxmi Towers BKC Road, Mumbai.
Where are Lupin offices?
Lupin has offices in Mumbai, Ankleshwar, Aurangabad, Bhopal and in 11 other locations.
How many offices does Lupin have?
Lupin has 18 offices.
Receive alerts for 300+ data fields across thousands of companies